Page 209 - Haematologica May 2022

Letters to the Editor
munotherapy/autoHCT as second line therapy are being conducted (TRANSFORM, clinicaltrials gov. Identifier: NCT03575351; ZUMA-7, clinicaltrials gov. Identifier: NCT03391466, and BELINDA, clinicaltrials gov. Identifier: NCT03570892) with potential practice-chang- ing implications. The number of patients who received novel therapies including CAR-T prior to autoHCT in this analysis is likely low as the first commercial CAR-T product was approved in late 2017 and the first targeted therapy for relapsed DLBCL in 2019 (polatuzumab vedotin-piiq).
Nonetheless, the retrospective data presented here suggest that autoHCT still has a role in r/r chemosensi- tive DLBCL even in later lines of therapy. If CAR-T ulti- mately becomes standard second line therapy, these data may serve as a benchmark for autoHCT outcomes in patients with 3+ prior lines of chemotherapy. Additionally, it would support offering an autoHCT in patients in the 3L+ setting in countries where CAR-T may not be available.
Matthew Mei,1 Mehdi Hamadani,2 Kwang W. Ahn,3,4 Yue Chen,4 Mohamed A. Kharfan-Dabaja,5 Craig Sauter2 and Alex F. Herrera1
1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA; 2BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; 3Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI; 4Center for International Blood and Marrow Transplant Research, Milwaukee, WI and 5Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA
Correspondence: MEHDI HAMADANI mhamadani@mcw.edu
doi:10.3324/haematol.2021.279999
Received: September 9, 2021.
Accepted: December 24, 2021.
Pre-published: February 3, 2022.
Disclosures: MH reports research support/funding from Spectrum Pharmaceuticals, Astellas Pharma; acts as a consultant for Janssen R &D, Incyte Corporation ,ADC Therapeutics, Verastem, Kite and is part of the speaker’s bureau of Sanofi Genzyme, AstraZeneca, BeiGene. MM reports research support/funding from TG Therapeutics, Epizyme, Inc., Bristol Meyers Squibb, BeiGene, Morphosys Agand has received honoraria from EUSA, Janssen Pharmaceuticals and Sanofi-Genzyme. AH reports research funding/consultancy fees from Bristol Myers-Squibb, Genentech, Merck, Seattle Genetics, AstraZena, ADC Therapeutics, KiTE Pharma, Gilead Sciences, Karyopharm, Takeda, Tubulis.
Contributions: MM and AH developed the concept and design of the study; YC and MH collected and assembled the data; KWA, YC and MH analyzed the data; MM, AH and MH prepared the first draft and wrote the manuscript. All authors interpreted data and helped to revise the manuscript.
Funding: the CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20- 1-2832 from the Office of Naval Research; support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial
entities: AbbVie; Accenture; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies Corporation; Adienne SA; Allovir, Inc.; Amgen, Inc.; Astellas Pharma US; bluebird bio, inc.; Bristol Myers Squibb Co.; CareDx; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Eurofins Viracor; ExcellThera; Fate Therapeutics; Gamida- Cell, Ltd.; Genentech Inc; Gilead; GlaxoSmithKline; Incyte Corporation; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Magenta Therapeutics; Medac GmbH; Merck & Co.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; MorphoSys; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncopeptides, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Seagen, Inc.; Stemcyte; Takeda Pharmaceuticals; Tscan; Vertex; Vor Biopharma; Xenikos BV.
Data sharing statement: CIBMTR supports accessibility of research in accord with the National Institutes of Health (NIH) Data Sharing Policy and the National Cancer Institute (NCI) Cancer Moonshot Public Access and Data Sharing Policy. The CIBMTR only releases de-identified datasets that comply with all relevant global regulations regarding privacy and confidentiality.
References
1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-1545.
2. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190.
3.Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2018;380(1):45-56.
4. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleu- cel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852.
5. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-bell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
6. Kansagra A, Farnia S, Majhail N. Expanding access to chimeric anti- gen receptor T-cell therapies: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2020;40:1-8.
7. Burki TK. CAR T-cell therapy roll-out in low-income and middle- income countries. Lancet Haematol. 2021;8(4):e252-e253.
8. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
9. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for ini- tial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
10. Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline ritux- imab-containing chemo-immunotherapy in diffuse large B cell lym- phoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(11):1729- 1736.
11. Commenges D, Andersen PK. Score test of homogeneity for survival data. Lifetime Data Anal. 1995;1(2):145-156; discussion 157-149.
12. Shah NN, Ahn KW, Litovich C, et al. Is autologous transplant in
relapsed DLBCL patients achieving only a PET+ PR appropriate in
the CAR T-cell era? Blood. 2021;137(10):1416-1423.
13. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory dif- fuse large B-cell lymphoma: results from the international SCHOL-
AR-1 study. Blood. 2017;130(16):1800-1808.
14. Jagadeesh D, Majhail NS, He Y, et al. Outcomes of rituximab-BEAM
versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020;126(10):2279-2287.
15. Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line sal- vage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51-57.
haematologica | 2022; 107(5)
1217